Helsinki heart study

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
Helsinki heart study On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Helsinki heart study All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Helsinki heart study
CDC on Helsinki heart study
Helsinki heart study in the news
Blogs on Helsinki heart study
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for Helsinki heart study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

The Helsinki Heart Study (HHS) is a randomized double-blind trial that assessed the primary cardiovascular preventive effect of elevation in HDL and decrease in non-HDL cholesterol with gemfifibrozil.

Study Description

Study Description
Study Design
Allocation	Randomized
Endpoint	Coronary heart disease
Masking	Double blind
Study Details
Primary Purpose	Prevention
Condition	Primary dyslipidemia
Intervention	Gemfibrosil Placebo
Population Size	4081 subjects

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number #.